Iterative Scopes, a Massachusetts-based AI Health startup, raised $30 million in Series A funding to apply the potential of AI to gastroenterology.
The round was led by Obvious Ventures and counted with the participation of Eli Lilly, Johnson & Johnson Innovation, Breyer Capital, and Seae Ventures, as well as angel investors like Lee Shapiro, Zach Weinberg, and Nat Turner. The round brings the startup’s total funding to $43.5 million since its founding in 2017.
Lotus Mallbris, M.D., Ph.D., Vice President of Immunology Development at Eli Lilly, and Nan Li, Managing Director at Obvious Ventures, will be joining Iterative Scopes’ board of directors. Mallbris referred to the firm’s decision to invest in the startup by stating: